{"entity":{"id":"nct06764940","kind":"trial","name":"A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases","aka":[],"tldr":"A phase 2 trial of Capecitabine in brain and spinal cord tumours, run by Biostar Pharma, Inc., now recruiting.","summary":"A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases is a phase 2 interventional study registered as NCT06764940 by Biostar Pharma, Inc., with 120 participants planned, started 2025-07-14 and due to reach its primary completion in 2027-01-15. Interventions recorded: Utidelone and Utidelone in combination with capecitabine.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06764940","url":"https://clinicaltrials.gov/study/NCT06764940"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["brain-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":["capecitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06764940","phase":"2","setting":"A Pivotal Phase II Clinical Trial of Utidelone Injection (UTD1) Plus Capecitabine (CAP) in HER2-negative Breast Cancer Patients With Brain Metastases","sponsor":"Biostar Pharma, Inc.","enrolled":120,"outcomes":[]},"route":"/trials/nct06764940/","neighbours":{"cancer":[{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"}]}}